San Francisco startup Construction Therapeutics is also engaged on an oral, once-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase review showed normal weight loss of close to 6% and it plans to start out A further mid-stage trial in direction of the end of the 12 months—that fo